Inhibrx Biosciences (INBX) Common Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Common Equity data on file, last reported at $8.0 million in Q4 2025.

• Common Equity for Q4 2025 came in at $8.0 million, down 94.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.0 million (down 94.02% YoY), and the FY2025 annual result was $8.0 million, down 94.02% from the prior year.
• Common Equity fell to $8.0 million in Q4 2025 per INBX's latest filing, from $36.8 million in the prior quarter.
• Over five years, Common Equity peaked at $219.4 million in Q2 2024 and troughed at -$24.8 million in Q2 2023.
• A 3-year average of $81.7 million and a median of $68.6 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity jumped 984.11% in 2024, then plunged 94.02% in 2025.
• A 3-year view of Common Equity shows it stood at $43.5 million in 2023, then jumped by 207.07% to $133.6 million in 2024, then sank by 94.02% to $8.0 million in 2025.
• Business Quant data shows INBX's Common Equity at $8.0 million in Q4 2025, $36.8 million in Q3 2025, and $68.6 million in Q2 2025.